Loading cancer entity…
Loading cancer entity…
Clinical trials
6,745 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,044)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06870487 | A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers | terminated | Phase 1 | 6 | PfizerINDUSTRY | 2 | May 8, 2026 | clinicaltrials |
| NCT04786093 | Durvalumab and Stereotactic Radiotherapy for Advanced NSCLC | terminated | Phase 2 | 1 | University of Texas Southwestern Medical CenterOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT05812274 |
| Apricity CARE to Improve ICI Outcomes of Ethnic/Racial Minority NSCLC Patients |
| terminated |
| N/A |
| 30 |
| Columbia UniversityOTHER |
| 1 |
| May 5, 2026 |
| clinicaltrials |
| NCT05983133 | A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors | terminated | Phase 1 | 68 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 2 | May 5, 2026 | clinicaltrials |
| NCT06192004 | Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy With Risk of Pneumonitis/ILD(LOOP) | terminated | — | 83 | AstraZenecaINDUSTRY | 1 | May 4, 2026 | clinicaltrials |
| NCT04902040 | Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies | terminated | Phase 1 / Phase 2 | 19 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT06235242 | GT201 Injection in Combination With Teraplizumab Injection for Treatment of Patients With Non-small Cell Lung Cancer | terminated | N/A | 2 | Grit BiotechnologyINDUSTRY | 1 | Apr 27, 2026 | clinicaltrials |
| NCT06513663 | Exercise as Maintenance Therapy in Advanced Lung Cancer | terminated | N/A | 2 | Indiana UniversityOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT03737994 | Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer | terminated | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Apr 23, 2026 | clinicaltrials |
| NCT06491225 | Autologous Tumor-Infiltrating Lymphocyte (GTE-001 Injection ) for Treatment of Patients With Advanced Lung Adenocarcinoma | terminated | Phase 1 | 2 | Grit BiotechnologyINDUSTRY | 1 | Apr 23, 2026 | clinicaltrials |
| NCT06974734 | A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies | terminated | Phase 1 | 8 | PfizerINDUSTRY | 2 | Apr 23, 2026 | clinicaltrials |
| NCT02257619 | Study of Itacitinib in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer | terminated | Phase 2 | 9 | Incyte CorporationINDUSTRY | 1 | Apr 21, 2026 | clinicaltrials |
| NCT02298153 | A Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma | terminated | Phase 1 | 29 | Incyte CorporationINDUSTRY | 1 | Apr 20, 2026 | clinicaltrials |
| NCT05861947 | A Phase 1 Clinical Trial of AUR106 in Patients With Relapsed Advanced Malignancies(JIVAN) | terminated | Phase 1 | 21 | Aurigene Discovery Technologies LimitedINDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT05397093 | ITIL-306 in Advanced Solid Tumors | terminated | Phase 1 | 1 | Instil BioINDUSTRY | 1 | Apr 15, 2026 | clinicaltrials |
| NCT02764086 | INTENSE: A Phase I/II Study of INhomogeneous Targeted Dose Escalation in Non-Small CEll Lung Cancer | terminated | Phase 1 / Phase 2 | 6 | Cancer Trials IrelandNETWORK | 1 | Apr 13, 2026 | clinicaltrials |
| NCT04892017 | Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors | terminated | Phase 1 | 91 | Deciphera Pharmaceuticals, LLCINDUSTRY | 1 | Apr 8, 2026 | clinicaltrials |
| NCT02679963 | Trial Evaluating Maintenance Olaparib in Patients With Platinum-sensitive Advanced Non-small Cell Lung Cancer(PIPSeN) | terminated | Phase 2 | 180 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT03348748 | Stereotactic Body Radiation Therapy Followed by Surgery in Treating Patients With Stage I-IIIA Non-small Cell Lung Cancer | terminated | Early Phase 1 | 20 | Roswell Park Cancer InstituteOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT05765734 | A Study of TAS3351 in NSCLC Patients With EGFRmt(TAS3351) | terminated | Phase 1 | 18 | Taiho Oncology, Inc.INDUSTRY | 5 | Apr 2, 2026 | clinicaltrials |
| NCT06186076 | A Study to Investigate Safety, Tolerability, PK and Anti-tumor Activity of TRX-221 in EGFRm NSCLC Patients | terminated | Phase 1 / Phase 2 | 19 | Therapex Co., LtdINDUSTRY | 1 | Apr 2, 2026 | clinicaltrials |
| NCT04234113 | Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors | terminated | Phase 1 | 115 | SOTIO Biotech AGINDUSTRY | 4 | Mar 27, 2026 | clinicaltrials |
| NCT04432207 | A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer | terminated | Phase 1 | 24 | Imugene LimitedINDUSTRY | 2 | Mar 25, 2026 | clinicaltrials |
| NCT04911166 | Phase I Trial of Atezolizumab and Interleukin-12 Gene Therapy in Metastatic Non-Small Cell Lung Cancer With Progression on First-Line Immunotherapy With or Without Chemotherapy | terminated | Phase 1 | 13 | The Methodist Hospital Research InstituteOTHER | 1 | Mar 24, 2026 | clinicaltrials |
| NCT06580938 | A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer | terminated | Phase 1 | 4 | PfizerINDUSTRY | 1 | Mar 23, 2026 | clinicaltrials |
| NCT04789668 | Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases | terminated | Phase 1 / Phase 2 | 8 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT06599502 | A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D Mutation(ALAFOSS-01) | terminated | Phase 1 | 17 | AstraZenecaINDUSTRY | 4 | Mar 18, 2026 | clinicaltrials |
| NCT03265496 | Correlation Between Tissue and Plasmatic EGFR in CBNPC With EGFR Mutation or Predictive Factor of EGFR Mutation(CONCORDE) | terminated | N/A | 21 | Centre Oscar LambretOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT06083454 | Ascorbate With Durvalumab in Non-Small Cell Lung Cancer (NSCLC) | terminated | Phase 1 | 1 | William ZeitlerOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT06173505 | Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC | terminated | Phase 1 / Phase 2 | 28 | Xencor, Inc.INDUSTRY | 8 | Mar 13, 2026 | clinicaltrials |
| NCT05636267 | Study of AK119 and AK112 With or Without Chemotherapy for NSCLC Patients | terminated | Phase 1 / Phase 2 | 59 | AkesoINDUSTRY | 1 | Mar 9, 2026 | clinicaltrials |
| NCT04222972 | A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)(AcceleRET-Lung) | terminated | Phase 3 | 223 | Hoffmann-La RocheINDUSTRY | 22 | Mar 5, 2026 | clinicaltrials |
| NCT06287463 | Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway | terminated | Phase 1 | 29 | Deciphera Pharmaceuticals, LLCINDUSTRY | 1 | Mar 5, 2026 | clinicaltrials |
| NCT04880382 | Integrative Analysis of Tumor Microenvironment and Optimization of Immunotherapy Duration in NSCL Cancer Patients(OPTIMUNELUNG) | terminated | Phase 2 | 8 | Institut BergoniéOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT03066206 | Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC | terminated | Phase 2 | 93 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT03366766 | Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable Non-Small Cell Lung Cancer | terminated | Phase 2 | 14 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT05233436 | PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors | terminated | Phase 1 | 21 | PfizerINDUSTRY | 2 | Feb 19, 2026 | clinicaltrials |
| NCT05578092 | A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway | terminated | Phase 1 | 64 | Mirati Therapeutics Inc.INDUSTRY | 2 | Feb 19, 2026 | clinicaltrials |
| NCT05462873 | A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors | terminated | Phase 1 | 30 | Novartis PharmaceuticalsINDUSTRY | 9 | Feb 17, 2026 | clinicaltrials |
| NCT03559049 | Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 25 | University of Michigan Rogel Cancer CenterOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT05551117 | A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors(Tamarack) | terminated | Phase 2 | 192 | MacroGenicsINDUSTRY | 9 | Feb 9, 2026 | clinicaltrials |
| NCT05443971 | Durvalumab and Grid Therapy for Non-small Cell Lung Cancer in Progression During or After Treatment With PACIFIC Regimen | terminated | Phase 1 | 4 | Mayo ClinicOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT04081688 | Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC | terminated | Phase 1 | 16 | Rutgers, The State University of New JerseyOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT04836429 | Photodynamic Therapy to Amplify the Response to Immunotherapy in Patients With Non-small Cell Lung Cancer With Pleural Disease | terminated | Phase 1 | 5 | Roswell Park Cancer InstituteOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT06560645 | A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation | terminated | Phase 1 | 42 | Prelude TherapeuticsINDUSTRY | 6 | Feb 2, 2026 | clinicaltrials |
| NCT06682806 | A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation | terminated | Phase 2 | 6 | Prelude TherapeuticsINDUSTRY | 2 | Feb 2, 2026 | clinicaltrials |
| NCT03436056 | PembRolIzuMab and Stereotactic Body Radiotherapy In Metastatic Non-small-cell lunG Cancer Patients(PRIMING) | terminated | Phase 1 | 2 | Royal Marsden NHS Foundation TrustOTHER | 1 | Jan 29, 2026 | clinicaltrials |
Data updated 22 days agoSource updated May 8, 2026source: clinicaltrials